GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Melodiol Global Health Ltd (OTCPK:COPHD) » Definitions » EV-to-Revenue

Melodiol Global Health (Melodiol Global Health) EV-to-Revenue : 0.48 (As of Jun. 22, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Melodiol Global Health EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Melodiol Global Health's enterprise value is $6.03 Mil. Melodiol Global Health's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $12.68 Mil. Therefore, Melodiol Global Health's EV-to-Revenue for today is 0.48.

The historical rank and industry rank for Melodiol Global Health's EV-to-Revenue or its related term are showing as below:

COPHD' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.48   Med: 16.45   Max: 4965.62
Current: 0.48

During the past 8 years, the highest EV-to-Revenue of Melodiol Global Health was 4965.62. The lowest was 0.48. And the median was 16.45.

COPHD's EV-to-Revenue is ranked better than
89.98% of 1018 companies
in the Drug Manufacturers industry
Industry Median: 2.21 vs COPHD: 0.48

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-22), Melodiol Global Health's stock price is $0.117. Melodiol Global Health's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $2.70. Therefore, Melodiol Global Health's PS Ratio for today is 0.04.


Melodiol Global Health EV-to-Revenue Historical Data

The historical data trend for Melodiol Global Health's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Melodiol Global Health EV-to-Revenue Chart

Melodiol Global Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial 6.02 65.21 15.02 4.83 0.97

Melodiol Global Health Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.02 - 4.83 - 0.97

Competitive Comparison of Melodiol Global Health's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Melodiol Global Health's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Melodiol Global Health's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Melodiol Global Health's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Melodiol Global Health's EV-to-Revenue falls into.



Melodiol Global Health EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Melodiol Global Health's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=6.029/12.678
=0.48

Melodiol Global Health's current Enterprise Value is $6.03 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Melodiol Global Health's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $12.68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Melodiol Global Health  (OTCPK:COPHD) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Melodiol Global Health's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.117/2.702
=0.04

Melodiol Global Health's share price for today is $0.117.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was $2.70.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Melodiol Global Health EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Melodiol Global Health's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Melodiol Global Health (Melodiol Global Health) Business Description

Traded in Other Exchanges
Address
145 Stirling Highway, Suite 5 CPC, Nedlands, WA, AUS, 6009
Melodiol Global Health Ltd is engaged in developing, registering, and commercialization of pharmaceutical-grade cannabis and hemp-based nutraceutical products and treatments for human and animal health. Its brands include Mernova: A licensed producer of cannabis products in Canada for sale under the Ritual brand banner. Sierra Sage Herbs: US-based developer of plant-based, beauty, and personal care brands Green Goo, Southern Butter, and Good Goo. impACTIVE: CBD topical products for athletes. Halucenex: Clinical stage psychedelics research and development operation. Creso Pharma Switzerland: CBD-related research, development, and commercialization.

Melodiol Global Health (Melodiol Global Health) Headlines

From GuruFocus

Sierra Sage Herbs Acquired By Creso Pharma

By PRNewswire PRNewswire 02-07-2022